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A B S T R AC T
Background: the PAI-1 rs1799889 polymorphism has been reported to be associated with susceptibility to ischemic stroke. However, 
the results of previous studies have been inconsistent or controversial. Hence, we performed a systematic review and meta-analysis to 
evaluate the association of PAI-1 rs1799889 polymorphism with ischemic stroke risk. Methods: A comprehensive literature search was 
performed on PubMed, Web of Science, Scopus, SciELO, CNKI, and CBD databases up to November 05, 2019. Pooled odds ratio (OR) with 
95% confidence interval (CI) were used to access the strength of this association in fixed- or random-effects model. Results: A total of 
44 case-control studies with 8,620 cases and 10,260 controls were selected. Pooled data showed a significant association between PAI-1 
rs1799889 polymorphism and ischemic stroke risk in the overall populations (GG vs. AA: OR = 0.791, 95% CI 0.633–0.988, p = 0.039; 
GA vs. AA: OR = 0.807, 95% CI 0.683–0.953, p = 0.012; and GG+GA vs. AA: OR = 0.795, 95% CI 0.637–0.993, p = 0.043). Subgroup analysis 
by ethnicity revealed a significant association in Asian and Mixed populations, but not in Caucasians. Moreover, stratified analysis by 
country of origin revealed an increased risk of ischemic stroke in Chinese populations, but not among Dutch (Netherlands) and Swedish. 
Conclusions: This meta-analysis result suggested that PAI-1 rs1799889 polymorphism was associated with an increased risk of ischemic 
stroke, especially in Asian and Mixed populations.
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INTRODUCTION
Stroke is the second leading cause of death globally and 
leading cause of long‐term disability worldwide (1). It pos­
es a huge threat to public health and is the leading cause 
of death in developed and developing countries (2). It is 
estimated that approximately 70% of new strokes are is­
chemic in origin, 51% stroke death, and 58% of stroke dis­
ability‐adjusted life years are because of ischemic stroke 
(3). The exact etiology of ischemic stroke is multifactorial 
and a complex interaction between modifiable and non‐
modifiable conventional risk and genetic factors could be 
behind the pathogenesis of this disease (4). Several var­
iants at low­penetrance and high­penetrance genes have 
been identified as potential ischemic stroke susceptibility 
loci. Numerous studies have found that Plasminogen acti­
vator inhibitor­1 (PAI­1) also serpin E1 was involved in the 
pathogenesis of ischemic stroke (5). Therefore, PAI­1 gene 
polymorphisms and its circulating levels may be associat­
ed with the development of ischemic stroke (5, 6).
Human PAI­1 gene is located at chromosome  7q21.3–
q22, contains 9 exons and spans 12.3 kb (7). PAI­1, a se­
creted single­chain glycoprotein, is one of  the early 
inflammatory response genes, and its expression level 
changes dramatically in response to many stimuli, in­
cluding growth factors and endotoxins (8, 9). Several 
polymorphisms within the PAI­1 gene have clearly been 
postulated to modulate the expression of PAI­1 (10, 11). 
Among SNPs of the PAI­1 gene, rs1799889 (4G/5G) pol­
ymorphism has been extensively studied in different 
disease (7, 12). PAI­1 rs1799889 is an inserted or deleted 
in the 4G sequence polymorphism in the PAI­1 promoter 
(4G/5G) at 675 bp upstream from the start of transcrip­
tional start site in the promoter region. Studying the as­
sociation of PAI­1 gene with different disease will help us 
to understand the mechanism of PAI­1 regulation and the 
role of PAI­1 in many physiological and pathological pro­
cesses (12, 13).
Studies have shown that the 4G/4G genotype has been 
linked to higher PAI­1 level, compared with the 5G/5G gen­
otype, with the heterozygous genotype associated with in­
termediate levels. In 2003, Chen et al., have reported that 
PAI­1 rs1799889 polymorphism alone is not associated 
with an increased risk of ischemic stroke. However, they 
revealed a significant contribution of PAI­1 4G/4G geno­
type with an increased triglyceride and decreased HDL 
cholesterol levels in the healthy group (14). There are sev­
eral numbers of epidemiological studies have evaluated 
association between PAI­1 rs1799889 polymorphism and 
ischemic stroke risk, but their results were inconsistent 
or even contradictory. For example, Adamski et al., and 
Esparza­García et al., have reported that PAI­1 rs1799889 
polymorphism was not associated with an increased risk 
of ischemic stroke in Polish and Mexican populations, re­
ceptively (15, 16). By contrast, Xu et al. results supported 
that PAI­1 rs1799889 polymorphism might be associated 
with an increased risk of ischemic stroke in Han Chinese 
(17). In recent years, some studies already studied po­
tential associations PAI­1 rs1799889 polymorphism with 
risk of ischemic stroke. Nevertheless, the results of these 
studies were not always consistent and the sample size 
of each study was also statistically insufficient. Thus, we 
performed a meta­analysis to offer a more comprehensive 
estimation of the association between PAI­1 rs1799889 and 
ischemic stroke susceptibility in globally populations.
MATERIALS AND METHODS
SEARCH STRATEGY
We have performed a  comprehensive literature search 
in PubMed, MEDLINE, EMBASE, Cochrane Library, Web 
of Science, Elsevier, SciELO, SID, WanFang, VIP, Chinese 
Biomedical Database (CBD) and Chinese National Knowl­
edge Infrastructure (CNKI) to identify all eligible studies 
on PAI­1 4G/5G (rs1799889) polymorphism and risk of is­
chemic stroke up to November 05, 2019. The following key­
words were adopted in the electronic searches: (“Ischemic 
Strok” OR “Atherothrombotic Cerebral Infarction”) AND 
(“Plasminogen Activator Inhibitor­1 Gene” OR “PAI­1” OR 
“SERPINE1”) AND (“insertion/deletion polymorphism” OR 
“4G/5G polymorphism” OR “4G/5G promoter polymor­
phism” OR “rs1799889” OR “−675 4G/5G”) AND (“Gene” 
OR “Genotype” OR “Polymorphism SNP’’ OR “Mutation” 
OR “Variation” OR “Variant”). Publication language was 
restricted to English, Chinese, and Farsi. Also a manual 
search of the reference lists performed to retrieved arti­
cles for additional potential studies.
INCLUSION AND EXCLUDING CRITERIA
The inclusion criteria for the gene association studies 
in this meta­analysis were as follows: 1) studies with 
case­control or cohort design; 2) full­text published stud­
ies; 3) studies evaluated the association between PAI­1 
rs1799889 polymorphism and ischemic stroke risk; and 
4) provided the genotype distribution in both cases and 
controls for estimating an odds ratio (OR) with 95% con­
fidence interval (CI). Additionally, studies were excluded 
if  one of the following criteria was fulfilled: 1) studies 
without detailed raw data regarding PAI­1 rs1799889 pol­
ymorphism; 2) case only studies; 3) family‐based, sibling, 
twins and linkage studies; 4) abstracts, review, letters, 
comments, conference editorials, presentations, case re­
ports, case series previous meta­analyses; 5) duplicates or 
overlapping studies. If the authors published two or more 
studies using the same data (with overlapping data), the 
newest publication or the publication with the largest 
sample size was included. There was no any limitation 
by ethnicity, race, placed or geography area. Moreover, 
non­English publications were translated and included 
in the meta­analysis.
DATA EXTRACTION
Two authors (HN and MJA) systematically extracted 
data from all eligible studies using a standardized form. 
Then, they have checked the data extraction results and 
reached consensus. If  different results were generated, 
the two authors carried out discussions until a consensus 
was reached or a third author was invited to resolve the 
disagreement and then a final decision were made by the 
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majority of the votes. The collected data were: first au­
thor’s name, publication year, country of origin, ethnic­
ity (Caucasian, Asian, African, Mixed populations), total 
numbers of cases and controls, genotypes frequencies of 
cases and controls, minor allele frequencies (MAFs) and 
Hardy­Weinberg equilibrium test in control subjects.
STATISTICAL ANALYSIS
An ethical approval was not necessary as this study was 
a meta­analysis based on previous studies. The strength of 
the associations PAI­1 rs1799889 (4G/5G) polymorphism 
and susceptibility to ischemic stroke was measured by 
odds ratios (ORs) with 95% confidence intervals (CIs). The 
statistical significance of the pooled OR was determined 
using the Z­test. Pooled estimates of the OR were obtained 
by calculating a weighted average of OR from each study. 
The pooled ORs was calculated under all five genetic mod­
els, i.e., allele (G vs. A), homozygote (GG vs. AA), hetero­
zygote (GA vs. AA), dominant (GG+GA vs. AA) and reces­
sive (GG vs. GA+AA). Between­studies heterogeneity was 
assessed by a Chi­squared Q­test and I2 statistics (P < 0.05). 
The heterogeneity between studies was estimated by Co­
chran’s χ2 based Q­statistic test, in which it was consid­
ered to be statistically significant at P ≤ 0.01. In addition, 
I2 test was used to quantify the effect of heterogeneity, 
with the range of 0 to 100%, and 0–40% meant no risk of 
heterogeneity, 30–60% meant a low risk of heterogeneity, 
50–90% meant substantial heterogeneity and 75–100% 
meant considerable heterogeneity. Accordingly, when be­
tween­study heterogeneity existed a random­effects mod­
el weighted (the DerSimonian­Laird method) was applied 
to give a more conservative result; otherwise, a fixed­ef­
fects model weighted (the Mantel­Haenszel method) 
method was selected. Hardy­Weinberg equilibrium (HWE) 
of the genotype distribution in controls was conducted 
by Pearson’s χ2 test, in which it was considered to be sta­
tistically significant at P ≤ 0.05. A subgroup analysis by 
 
Fig. 1 The study selection and inclusion process. 
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MAFs HWEGenotypes Allele Genotypes Allele
AA AG GG A G AA AG GG A G
Catto 1997 UK(Caucasian) 558/172 150 274 134 574 542 56 80 36 192 152 0.442 0.454
Liu 1998 China(Asian) 107/95 44 43 20 131 83 25 48 22 98 92 0.484 0.910
Jeppesen 1998 Denmark(Caucasian) 177/93 48 92 37 188 166 26 49 18 101 85 0.457 0.552
Endler 2000 Austria(Caucasian) 136/115 42 63 31 147 125 48 48 19 144 86 0.373 0.287
Elbaz 2001 Netherlands(Caucasian) 461/461 125 223 113 473 449 129 245 87 503 419 0.454 0.123
Gottl 2001 Germany(Caucasian) 198/951 65 91 42 221 175 275 473 203 1023 879 0.462 0.988
Bang 2001 Korea(Asian) 60/100 25 25 10 75 45 21 53 26 95 105 0.525 0.530
Sun 2001 China(Asian) 50/60 21 20 9 62 38 15 30 15 60 60 0.500 1.000
Zhang 2001a China(Asian) 95/60 50 31 14 131 59 15 30 15 60 60 0.500 1.000
Zhang 2001b China(Asian) 65/60 28 25 12 81 49 16 35 9 67 53 0.441 0.157
Kain 2002 UK(Caucasian) 101/102 22 58 21 102 100 36 54 12 126 78 0.382 0.075
Hindorff 2002 USA(Caucasian) 41/385 7 24 10 38 44 115 187 83 417 353 0.458 0.668
Crainich 2003 USA(Caucasian) 265/753 81 143 41 305 225 200 387 166 787 719 0.477 0.410
Zhang 2003 China(Asian) 113/121 48 47 18 143 83 23 70 28 116 126 0.521 0.080
Chen 2003 Taiwan(Asian) 100/150 40 46 14 126 74 58 68 24 184 116 0.386 0.588
Zhan 2003 China(Asian) 54/83 11 30 13 52 56 25 30 6 80 42 0.344 0.485
Guan 2004 China(Asian) 222/215 75 105 42 255 189 46 121 48 213 217 0.504 0.065
Yeh 2004 China(Asian) 213/200 79 103 31 261 165 71 102 27 244 156 0.390 0.309
Yi 2004 China(Asian) 52/57 20 22 10 62 42 28 27 2 83 31 0.271 0.138
Tang 2005 China(Asian) 122/50 66 35 21 167 77 13 26 11 52 48 0.48 0.768
Jood 2005 Sweden(Caucasian) 600/600 162 307 131 631 569 186 280 134 652 548 0.456 0.144
Van Goor 2005 Netherlands(Caucasian) 123/123 33 61 29 127 119 36 58 29 130 116 0.472 0.550
Wiklund 2005a Sweden(Caucasian) 89/218 42 33 14 117 61 67 109 42 243 193 0.442 0.844
Wiklund 2005b Sweden(Caucasian) 222/542 94 85 43 273 171 174 261 107 609 475 0.438 0.609
Xu 2006 China(Asian) 72/77 15 29 28 59 85 5 35 37 45 109 0.707 0.386
Komitopoulou 2006 Greece(Caucasian) 87/101 23 50 14 96 78 23 55 23 101 101 0.500 0.370
Attia 2007 Australia(Caucasian) 171/182 63 71 37 197 145 62 89 31 213 151 0.415 0.922
Saidi 2007 Tunisia(African) 135/118 23 74 38 120 150 33 58 27 124 112 0.475 0.875
Liu 2008 China(Asian) 220/140 48 114 58 210 230 43 70 27 156 124 0.497 0.876
Tang 2008 China(Asian) 90/30 40 36 16 116 68 6 19 5 31 29 0.483 0.142
Adamski 2009 Poland(Caucasian) 390/291 120 189 81 429 351 89 136 66 314 268 0.377 0.018
Sabino 2011 Brazil(Mixed) 127/201 33 52 42 118 136 93 65 43 251 151 0.376 ≤0.001
Balcerzyk 2011 Poland(Caucasian) 70/133 23 35 12 81 59 47 60 26 154 112 0.421 0.389
Pruissen 2011 Netherlands(Caucasian) 841/310 261 111 29 633 169 71 157 82 299 321 0.518 0.802
Maguire 2011 Australia(Caucasian) 612/600 198 279 135 675 549 169 302 129 640 560 0.467 0.784
Assawamakin 2012 Taiwan(Asian) 179/229 51 97 31 199 159 67 110 52 244 214 0.467 0.594
Babu 2012 India(Asian) 516/513 236 238 42 710 322 258 223 32 739 287 0.284 0.028
Huang 2014 China(Asian) 285/919 115 156 14 386 184 310 520 89 1140 698 0.380 ≤0.001
Natesirinilkul 2014 Thailand(Asian) 29/40 2 20 7 24 34 1 32 7 34 46 0.575 ≤0.001
Supanc 2014 Croatia(Caucasian) 155/150 44 51 60 139 171 28 46 76 102 198 0.660 ≤0.001
García 2015 Mexico(Mixed) 204/204 23 94 87 140 268 16 87 101 119 289 0.708 0.646
Ranellou 2015 Greece(Caucasian) 40/65 2 36 2 40 40 4 44 17 52 78 0.600 ≤0.001
Akhter 2017 India(Asian) 100/100 34 56 10 124 76 24 54 22 102 98 0.490 0.421
Coen Herak 2017 Croatia(Caucasian) 73/100 19 37 17 75 71 27 53 20 107 93 0.465 0.514
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ethnicity, country of origin, and source of controls was 
performed to explore potential sources of between­study 
heterogeneity (18, 19). To check the stability of the pooled 
data, a  sensitivity analysis was performed by omitting 
each individual study in turn from the all selected stud­
ies and reanalyzing the remainder. Moreover, sensitivity 
analysis was performed by excluding HWE­violating stud­
ies. The potential publication bias was explored visually by 
Egger’s linear regression test and Begg’s quantitative test 
(20). The asymmetric plot of Egger’s test and the P­value 
of Begg’s test less than 0.05 were considered a significant 
publication bias. All statistical analyses were performed 
using Comprehensive Meta­Analysis (CMA) Software ver­
sion 2.0 (Biostat, Englewood, NJ). All tests were two­sided, 
and the P values of < 0.05 were considered statistically 
significant.
RESULTS
CHARACTERISTICS OF INCLUDED STUDIES
By electronic and manual searches concerning the associa­
tion of PAI­1 rs1799889 polymorphism and ischemic stroke 
risk, 297 relevant studies up to November 05, 2019 were 
identified. After reading titles and abstracts, 139 irrelevant 
and duplicate articles were excluded. Another 95 articles 
were subsequently excluded because not reporting useful 
data for meta­analysis, review, case only study, and not be­
ing case­control studies. Finally, a total of 44 case­control 
studies (5, 14–16, 21–49) with 8,620 ischemic stroke cases 
and 10,260 controls were included in the meta‐analysis. 
Characteristics of included studies are presented in Ta­
ble 1. All eligible studies were published in English and 
Chinese between April 1997 and November 2017. Among 
Fig. 2A Forest plot for the association of PAI-1 rs1799889 Polymorphism with Susceptibility to Ischemic Stroke: overall population 
(homozygote model: GG vs. AA).
A
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them, 21 studies were based on Caucasian populations 
(5,410 cases and 6,438 controls), 20 studies based on Asian 
populations (3,137 cases and 3,700 controls), two studies 
based on mixed populations (331 cases and 405 controls), 
and one study was based on African populations (135 cas­
es and 118 controls). The selected studies were conducted 
in UK, USA, Sweden, Greece, Australia, Austria, Poland, 
Denmark, Netherlands, Germany, Croatia, China, Taiwan, 
Thailand, Korea, India, Brazil, Mexico and Tunisia. The al­
lele, genotype and minor allele frequency (MAF) distribu­
tions in the cases and controls are shown in Table 1. More­
over, the distribution of genotypes in the controls was in 
agreement with Hardy­Weinberg equilibrium (HWE) for 
all selected studies, except for seven studies (Table 1).
QUANTITATIVE DATA SYNTHESIS
The summary of the meta­analysis of the association of be­
tween PAI­1 rs1799889 polymorphism and ischemic stroke 
are shown in Table 2. Pooled data revealed that there was 
a  significant association between PAI­1 rs1799889 poly­
morphism and an increased risk of ischemic stroke in 
the overall population under three genetic models, i.e., 
homozygote (GG vs. AA: OR = 0.791, 95% CI 0.633–0.988, 
p = 0.039, Fig 2A), heterozygote (GA vs. AA: OR = 0.807, 95% 
CI 0.683–0.953, p = 0.012) and dominant (GG+GA vs. AA: 
OR = 0.795, 95% CI 0.637–0.993, p = 0.043, Fig 2B). More­
over, we have performed subgroup analyses by  ethnicity 
and country of origin. Subgroup analysis by ethnicity 
showed that there was a significant association between 
PAI­1 rs1799889 polymorphism and ischemic stroke risk in 
 Fig. 2B Forest plot for the association of PAI-1 rs1799889 Polymorphism with Susceptibility to Ischemic Stroke: overall population 
(dominant model: GG + GA vs. AA).
B
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Asians (G vs. A: OR = 0.829, 95% CI 0.697–0.987, p = 0.035; 
GA vs. AA: OR = 0.663, 95% CI 0.518–0.848, p = 0.001; and 
GG+GA vs. AA: OR = 0.683, 95% CI 0.521–0.897, p = 0.006) 
and Mixed population (G  vs. A: OR = 3.255, 95% CI 
 1.041–10.181, p = 0.043), but not in Caucasians. When strat­
ified analysis by country of origin performed a significant 
association was found among Chinese population (G vs.  A: 
OR = 0.798, 95% CI 0.637–0.999, p = 0.049; GG vs. AA: 
OR = 0.640, 95% CI 0.421–0.972, p = 0.036, Fig 2C; GA vs. 
AA: OR = 0.577, 95% CI 0.427–0.778, p ≤ 0.001; and  GG+GA 
vs. AA: OR = 0.620, 95% CI 0.438–0.876, p = 0.007), but not 
in Dutch (Netherlands) and Swedish.
BETWEEN-STUDY HETEROGENEITY TEST
As shown in Table 2, there was statistically moderate to high 
between­study heterogeneity in the overall population un­
der all five genetic models, i.e., allele (I2 = 91.95, PH ≤ 0.001), 
homozygote (I2 = 79.67, PH ≤ 0.001), heterozygote (I2 = 77.98, 
PH ≤ 0.001), dominant (I2 = 89.86, PH ≤ 0.001), and recessive 
(I2 = 78.03, PH ≤ 0.001). To explore the potential sources of 
heterogeneity, subgroup analyses by ethnicity, country 
of origin and HWE was performed. The results suggested 
that the above mentioned factors did not contribute to be­
tween­study heterogeneity in the current meta­analysis.
SENSITIVITY ANALYSIS
A sensitivity analysis was used to test the effects of each 
study on pooled ORs. There were no significant differ­
ences observed upon removal of any of the studies, sug­
gesting that our findings were statistically robust and 
reliable. Moreover, we performed sensitivity analysis 
by excluding the HWE­violating study (Figure 3). When 
this study was excluded, the results were not changed in 
overall population and also by subgroup analyses, indi­
cating that our meta­analysis was statistically robust and 
reliable.
PUBLICATION BIAS
Begg’s funnel plot and Egger’s test were inspected to evaluate 
the possible publication bias in this meta­analysis. Results 
of publication bias were shown in Table 2 and Figure 4. The 
shape of the funnel did not show any obvious asymmetry in 
all of the genetic models. Moreover, Egger’s test was statis­
tically revealed that there was no a significant bias under all 
five genetic models in the overall populations all five genetic 
models, i.e., allele (PBeggs = 0.112; PEggers = 0.859), homozygote 
(PBeggs = 0.198; PEggers = 0.307), heterozygote (PBeggs = 0.107; 
PEggers = 0.267), dominant (PBeggs = 0.172; PEggers = 0.841), and 
recessive (PBeggs = 0.723; PEggers = 0.876).
DISCUSSION
The PAI­1 rs1799889 polymorphism association to ischemic 
stroke was first described by Catto et al. in 1997 (44). Since 
several epidemiological studies have been evaluated asso­
ciation between PAI­1 rs1799889 polymorphism and risk 
of ischemic stroke (17, 45). However, the results of these 
studies remain contradictory. It is clear that a single study 
may fail to demonstrate a complicated genetic relationship 
completely because of small sample size, which has low 
statistical power. Larger studies could overcome these dis­
advantages. Therefore, we performed a comprehensive me­
ta­analysis of all eligible studies evaluated the association 
of PAI­1 rs1799889 polymorphism with risk ischemic stroke.
	  
Fig.	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Fig. 2C Forest plot for the association of PAI-1 rs1799889 Polymorphism with Susceptibility to Ischemic Stroke: Chinese population 
(homozygote model: GG vs. AA).
C
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Tab. 2 Summary risk estimates for association of PAI-1 rs1799889 polymorphism with risk of ischemic stroke.
Subgroup Genetic Model Type of Model
Heterogeneity Odds Ratio Publication Bias
I2 (%) PH OR 95% CI Ztest POR PBeggs PEggers
Overall G vs. A Random 91.95 ≤0.001 0.854 0.727-1.003 -1.928 0.054 0.112 0.859
GG vs. AA Random 79.67 ≤0.001 0.791 0.633-0.988 -2.067 0.039 0.198 0.307
GA vs. AA Random 77.98 ≤0.001 0.807 0.683-0.953 -2.526 0.012 0.107 0.267
GG+GA vs. AA Random 89.86 ≤0.001 0.795 0.637-0.993 -2.021 0.043 0.172 0.841
GG vs. GA+AA Random 78.03 ≤0.001 0.868 0.726-1.038 -1.555 0.120 0.723 0.876
Ethnicity
Caucasian G vs. A Random 87.76 ≤0.001 1.076 0.884-1.311 0.730 0.465 0.620 0.561
GG vs. AA Random 56.91 0.003 1.002 0.807-1.243 0.018 0.986 0.921 0.907
GA vs. AA Random 55.09 0.005 0.978 0.822-1.163 -0.255 0.798 0.373 0.588
GG+GA vs. AA Random 61.67 0.001 0.983 0.825-1.172 -0.189 0.850 0.428 0.611
GG vs. GA+AA Random 48.82 0.017 0.994 0.839-1.178 -0.072 0.942 0.766 0.681
Asian
G vs. A Random 77.84 ≤0.001 0.829 0.697-0.987 -2.113 0.035 0.820 0.389
GG vs. AA Random 94.75 ≤0.001 0.988 0.446-2.189 -0.031 0.975 0.581 0.497
GA vs. AA Random 71.16 ≤0.001 0.663 0.518-0.848 -3.276 0.001 0.144 0.014
GG+GA vs. AA Random 79.02 ≤0.001 0.683 0.521-0.897 -2.749 0.006 0.284 0.079
GG vs. GA+AA Random 49.29 0.007 0.881 0.704-1.102 -1.111 0.267 0.314 0.410
Mixed
G vs. A Random 96.28 ≤0.001 3.255 1.041-10.181 2.029 0.043 NA NA
GG vs. AA Random 90.73 0.001 1.301 0.292-5.795 0.345 0.730 NA NA
GA vs. AA Random 83.11 0.015 1.333 0.455-3.908 0.524 0.600 NA NA
GG+GA vs. AA Random 89.45 0.002 1.310 0.367-4.670 0.416 0.678 NA NA
GG vs. GA+AA Random 86.25 0.007 1.156 0.492-2.719 0.333 0.739 NA NA
Country
China G vs. A Random 80.33 ≤0.001 0.798 0.637-0.999 -1.967 0.049 0.766 0.871
GG vs. AA Random 71.92 ≤0.001 0.640 0.421-0.972 -2.094 0.036 0.373 0.836
GA vs. AA Random 70.45 ≤0.001 0.577 0.427-0.778 -3.599 ≤0.001 0.373 0.104
GG+GA vs. AA Random 80.61 ≤0.001 0.620 0.438-0.876 -2.706 0.007 0.766 0.383
GG vs. GA+AA Random 52.16 0.010 0.895 0.680-1.178 -0.793 0.428 0.373 0.243
Netherlands G vs. A Random 99.29 ≤0.001 0.498 0.095-2.260 -0.822 0.411 1.000 0.959
GG vs. AA Random 96.06 ≤0.001 0.586 0.184-1.862 -0.907 0.364 1.000 0.920
GA vs. AA Random 97.24 ≤0.001 0.519 0.089-3.014 -0.731 0.465 1.000 0.825
GG+GA vs. AA Random 98.94 ≤0.001 0.410 0.052-3.208 -0.849 0.396 1.000 0.899
GG vs. GA+AA Random 97.82 ≤0.001 0.518 0.093-2.885 -0.751 0.453 1.000 0.730
Sweden G vs. A Random 75.65 0.016 0.855 0.647-1.129 -1.105 0.269 0.296 0.210
GG vs. AA Fixed 56.85 0.099 0.907 0.711-1.155 -0.794 0.427 0.296 0.219
GA vs. AA Random 87.54 ≤0.001 0.737 0.401-1.352 -0.986 0.324 1.000 0.341
GG+GA vs. AA Random 86.60 0.001 0.751 0.437-1.292 -1.034 0.301 0.296 0.328
GG vs. GA+AA Fixed 0.00 0.829 0.951 0.769-1.177 -0.459 0.646 0.296 0.321
HWE G vs. A Random 92.62 ≤0.001 0.843 0.700-1.015 -1.799 0.072 0.161 0.964
GG vs. AA Random 80.14 ≤0.001 0.778 0.609-0.994 -2.010 0.044 0.277 0.418
GA vs. AA Random 79.04 ≤0.001 0.765 0.633-0.926 -2.754 0.006 0.107 0.346
GG+GA vs. AA Random 90.70 ≤0.001 0.763 0.590-0.988 -2.051 0.040 0.266 0.932
GG vs. GA+AA Random 79.09 ≤0.001 0.871 0.714-1.062 -1.365 0.172 0.743 0.938
NA: Not Applicable. 
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In the current meta­analysis, we have selected a total of 
44 eligible case­control studies with 8,620 ischemic stroke 
cases and 10,260 controls to evaluate the association of 
PAI­1 rs1799889 polymorphism with ischemic stroke risk. 
Our pooled data showed that PAI­1 rs1799889 polymor­
phism was significantly associated with an increased risk 
of ischemic stroke in the overall population. Moreover, 
subgroup analyses revealed that PAI­1 rs1799889 polymor­
phism was associated with significantly increased risk of 
ischemic stroke in Asian and mixed populations, but not 
in Caucasians. When stratified analysis by country of ori­
gin performed a significant association was found among 
Chinese population, but not in Dutch (Netherlands) and 
Swedish. This finding indicated that the carriers with the 
4G allele of the PAI­1 rs1799889 polymorphism in Asians 
and mixed populations might be predisposed to ischemic 
stroke, but not in Caucasian populations. Moreover, this 
finding suggested a  possible influence among environ­
mental exposures and different genetic backgrounds in 
development of ischemic stroke in different populations. 
Therefore, more studies are warranted to further vali­
date genetic background difference in the effect of PAI­1 
rs1799889 polymorphism in susceptibility to ischemic 
stroke, especially in Caucasians. Cao et al., in a meta­anal­
ysis of eleven case­control studies with 1,358 cases and 
1,134 controls evaluated the association of PAI­1 rs1799889 
polymorphism with susceptibility to ischemic stroke in 
the Chinese population. Their results showed a  signifi­
cant association between PAI­1 rs1799889 polymorphism 
and ischemic stroke risk. However, their meta­analysis 
results reliability and the number of studies are consid­
erably smaller than that needed to receive the robust con­
clusions (45). Here, we have extended the meta­analysis 
with a more relevant recently published studies and sub­
group analysis by ethnicity. Moreover, Hu et al., in me­
ta­analysis of 39 studies with 8,336 cases and 14,403 con­
trols evaluated PAI­1 polymorphisms with risk of stroke. 
Their results revealed a significant association between 
PAI­1 rs1799889 polymorphism and an increased risk of 
ischemic stroke in adult, but not pediatric. Their strati­
fied analysis showed a significant association in Asians, 
but not Caucasians. Moreover, they found that PAI­1–844 
G>A, but not 11,053  T>G polymorphism was associated 
with an increased risk of ischemic stroke and a tendency 
 
Fig.	  3	  Forest	  plot	  for	  the	  association	  of	  PAI-­‐1	  rs1799889	  Polymorphism	  with	  
Susceptibility	  to	  Ischemic	  Stroke	  after	  excluding	  Hardy-­‐Weinberg	  equilibrium	  (HWE)	  
violating	  studies	  under	  the	  homozygote	  genetic	  model	  (GG	  vs.	  AA).	  
	  
Fig. 3 Forest plot for the association of PAI-1 rs1799889 Polymorphism with Susceptibility to Ischemic Stroke after excluding Hardy-
Weinberg equilibrium (HWE) violating studies under the homozygote genetic model (GG vs. AA).
40 Mohammadali Jafari et al.  Acta Medica (Hradec Králové)
 
of  PAI­1 rs1799889 polymorphism towards a decreased risk 
of hemorrhagic stroke (50).
Between­study heterogeneity is a  common issue in 
a  meta­analysis on genetic association (51–53). It could 
be attributable to differences in several factors such as 
environmental factors, including criteria or methodolog­
ical factors in design and conduct of the studies (54, 55). 
Thus, identifying the potential sources of heterogeneity is 
one of the most important goals of meta­analysis. When 
all the eligible studies were pooled in this meta­analysis, 
there was significant between­study heterogeneity under 
all genetic models. However, after subgroup analyses by 
ethnicity the heterogeneity not effectively disappeared 
or decreased, which indicated that ethnicity did not play 
a crucial role in the existence of between­study heteroge­
neity in the current meta­analysis.
The current meta­analysis had some advantages. 





Fig.	  4	  Begg’s	  funnel	  plots	  of	  between	  PAI-­‐1	  rs1799889	  Polymorphism	  with	  
Susceptibility	  to	  Ischemic	  Stroke.	  A:	  heterozygote	  model	  (GA	  vs.	  AA);	  B:	  dominant	  model	  
(GG+GA	  vs.	  AA).	  Each	  point	  represents	  a	  separate	  study	  for	  the	  indicated	  association.	  	  
	  
Fig. 4 Begg’s funnel plots of between PAI-1 rs1799889 Polymorphism with Susceptibility to Ische ic Stroke. A: heterozygote model (GA vs. 
AA); B: dominant model (GG+GA vs. AA). Each point represents a separate study for the indicated association.
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ta­analysis to evaluate association of PAI­1 rs1799889 pol­
ymorphism with ischemic stroke, which involved Asian, 
Caucasian, mixed populations. Second, the current me­
ta­analysis search not restricted to studies published in 
indexed journals. Third, we have evaluated the association 
under all five genetic models. Forth, there was no evidence 
of publication bias by Begg’s funnel plot and Egger’s test in 
this meta­analysis. Finally, sensitivity analysis confers the 
reliability and stability of our pooled data. However, some 
limitations of this meta­analysis should be mentioned. 
First, the sample size of the included studies was not large 
enough by ethnicity among African and Mixed popula­
tions. Therefore, there was a lack of statistical power to bet­
ter calculate association of PAI­1 rs1799889 polymorphism 
with risk of stroke among African and Mixed populations. 
Second, all included studies were published in English or 
Chinese which may be brought some bias. Third, in this 
meta­analysis between­study heterogeneity was detected 
under all five genetic models in the overall population and 
by subgroup analyses, which may be distorting the pooled 
data. Finally, our results were based on single­factor esti­
mations without adjustment for other risk factors such as 
age, gender, and environmental factors.
In summary, this meta­analysis result revealed that 
PAI­1 rs1799889 polymorphism was significantly associat­
ed with an increased risk of ischemic stroke, especially in 
Asian populations. Moreover, there was a significant as­
sociation between PAI­1 rs1799889 polymorphism and is­
chemic stroke risk. Future studies with large sample sizes 
and well designs in the Mixed and African populations and 
gene­gene and gene­environment interaction studies are 
warranted to confirm these findings.
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